Detalhe da pesquisa
1.
Changes in tumor-to-blood ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT.
Eur J Nucl Med Mol Imaging
; 51(3): 841-851, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37947848
2.
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer.
Radiology
; 308(1): e222148, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37432081
3.
Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy.
Eur J Nucl Med Mol Imaging
; 50(7): 2196-2209, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36859618
4.
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.
Eur J Nucl Med Mol Imaging
; 50(5): 1466-1486, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36604326
5.
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).
Eur J Nucl Med Mol Imaging
; 50(9): 2830-2845, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246997
6.
Bone Metastases in Patients with Pancreatic NETs: Prevalence and Prognosis.
Horm Metab Res
; 55(12): 827-834, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37611636
7.
[18F]FDG PET/MRI in children suffering from lymphoma: does MRI contrast media make a difference?
Eur Radiol
; 33(11): 8366-8375, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37338559
8.
Recurrent prostate cancer: combined role for MRI and PSMA-PET in 68Ga-PSMA-11 PET/MRI.
Eur Radiol
; 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38038758
9.
Reduction of emission time for [68Ga]Ga-PSMA PET/CT using the digital biograph vision: a phantom study.
Q J Nucl Med Mol Imaging
; 67(1): 57-68, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34309334
10.
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.
Eur J Nucl Med Mol Imaging
; 49(12): 4271-4281, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35767071
11.
Phantom-based acquisition time and image reconstruction parameter optimisation for oncologic FDG PET/CT examinations using a digital system.
BMC Cancer
; 22(1): 899, 2022 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35978274
12.
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.
Lancet Oncol
; 22(8): 1115-1125, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34246328
13.
Prostate-specific Membrane Antigen PET in Prostate Cancer.
Radiology
; 299(2): 248-260, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33787338
14.
Value of PET imaging for radiation therapy.
Strahlenther Onkol
; 197(9): 1-23, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34259912
15.
Just another "Clever Hans"? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer.
Eur J Nucl Med Mol Imaging
; 48(10): 3141-3150, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33674891
16.
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis.
Eur J Nucl Med Mol Imaging
; 48(4): 1200-1210, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32970216
17.
Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients.
Eur J Nucl Med Mol Imaging
; 48(13): 4377-4385, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34137945
18.
False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial.
Eur J Nucl Med Mol Imaging
; 48(2): 501-508, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32808077
19.
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.
BMC Cancer
; 21(1): 512, 2021 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33962579
20.
Analysis of risk factors and prognosis in differentiated thyroid cancer with focus on minimal extrathyroidal extension.
BMC Endocr Disord
; 21(1): 161, 2021 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34376175